Repurposing disulfiram as treatment for metastatic colorectal cancerAn investigator initiated clinical phase II trial

ABSTRACT: Primary objective: Disease-control rate (complete response, partial response and/or stable disease >= 18 weeksTo investigate efficacy and safety of the treatment combination irinotecan, disulfiram and copper in patients with metastatic colorectal cancer having developed resistance to irinotecan. Primary objective: Disease-control rate (complete response, partial response and/or stable disease >= 18 weeks

DISEASE(S): Metastatic, Non-resectable And Irinotecan-resistant Colorectal Cancer,Colorectal Cancer Metastatic

PROVIDER: 2539387 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR